Primary Brain Tumors - Yale Medicine Explains

Why It Matters

Advanced, multidisciplinary treatment at Yale improves survival and functional outcomes for patients with otherwise lethal brain tumors, while accelerating the translation of research into clinical practice.

Key Takeaways

• Primary brain tumors arise within brain tissue, not metastases.
• Gliomas range from low‑grade indolent to aggressive glioblastoma.
• Maximal safe resection uses GPS, functional MRI, and neuro‑monitoring.
• Post‑surgery therapy includes radiation, chemotherapy, and clinical trial options.
• Multidisciplinary care at Yale integrates research to improve patient outcomes.

Summary

The video explains primary brain tumors—lesions that originate in the brain itself rather than spreading from elsewhere—and outlines Yale Medicine’s comprehensive approach to diagnosis and treatment. It distinguishes benign from malignant forms, focusing on gliomas, which span low‑grade, slow‑growing tumors to high‑grade glioblastoma, the most aggressive subtype.

Key clinical insights include the necessity of maximal safe resection, guided by GPS‑assisted navigation, functional MRI to map language and motor areas, and intra‑operative neurophysiology monitoring (EEG, motor, sensory, cranial nerve). These technologies aim to remove as much tumor as possible while preserving neurological function, a factor directly linked to improved survival.

Dr. Kelley emphasizes that despite advanced surgery, gliomas often infiltrate beyond resectable margins, requiring adjuvant radiation, chemotherapy, and enrollment in clinical trials. He highlights Yale’s multidisciplinary team—neurosurgeons, radiologists, oncologists, and laboratory scientists—working together to translate cutting‑edge research into patient care.

The implications are clear: integrating precision imaging, real‑time monitoring, and research‑driven therapies can extend life expectancy and maintain quality of life for brain‑tumor patients, setting a benchmark for other institutions aiming to combine surgical excellence with innovative systemic treatments.

Original Description

For more information on gliomas or #YaleMedicine, visit: https://www.yalemedicine.org/conditions/primary-brain-tumors.

Brain cells can sometimes divide uncontrollably to form a tumor within the brain, the covering of the brain, or on the nerves in the brain. This type of tumor is called a primary brain tumor and is different rom secondary brain tumors, or those that occur by the spread (or metastasis) of tumors from other organs in the body. Whether benign (noncancerous) or malignant (cancerous), all patients with brain tumors require immediate attention. At Yale Medicine, our experienced doctors use their expertise and state-of-the-art equipment to diagnose, manage and treat brain tumors. We classify primary brain tumors by type and the World Health Organization (WHO) grade. Types of primary tumors are classified by the cell from which they originate. A glioma, for instance (which is the focus of this discussion) is a common type of primary brain tumor. Originating from specialized cells of the central nervous system called astrocytes or oligodendrocytes, this type of brain tumor is called astrocytomas or oligodendrogliomas. Grading of primary brain tumors helps distinguish their clinical behavior and provide insight with regards to tumor growth, recurrence and prognosis. With regards to gliomas, a WHO Grade 1 tumor is the most benign and referred to as pilocytic astrocytoma. These are more commonly encountered in children. Grade 2 gliomas are often referred to as “infiltrative glioma” or “low-grade gliomas” (LGGs) given their slow, infiltrative growth patterns. Grades 3 and 4, anaplastic glioma and glioblastoma, or glioblastoma multiforme (GBM), respectively are considered “high-grade gliomas" (HGGs) because they behave more aggressively with a faster growth rate and are considered malignant, or cancerous. High grade gliomas can arise from low grade gliomas, or may be what's called “de novo” (meaning they arise primarily as a high grade tumor) and have specific mutations related to each.

0:00 Primary Brain Tumors

1:03 Surgical Intervention

2:59 Systemic Therapies